In the last trading session, 3.89 million Verrica Pharmaceuticals Inc (NASDAQ:VRCA) shares changed hands as the company’s beta touched 1.79. With the company’s per share price at $0.52 changed hands at -$0.06 or -10.28% during last session, the market valuation stood at $48.34M. VRCA’s last price was a discount, traded about -1626.92% off its 52-week high of $8.98. The share price had its 52-week low at $0.38, which suggests the last value was 26.92% up since then. When we look at Verrica Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.57 million shares, with the 3-month average coming to 305.07K.
Analysts gave the Verrica Pharmaceuticals Inc (VRCA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.20. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VRCA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) trade information
Instantly VRCA was in red as seen at the end of in last trading. With action -10.64%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -92.58%, with the 5-day performance at -10.64% in the red. However, in the 30-day time frame, Verrica Pharmaceuticals Inc (NASDAQ:VRCA) is -3.19% down. Looking at the short shares, we see there were 2.97 million shares sold at short interest cover period of 10.78 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 95.67% from its current market value. According to analyst projections, VRCA’s forecast low is 10 with 14 as the target high. To hit the forecast high, the stock’s price needs a -2592.31% plunge from its current level, while the stock would need to soar -1823.08% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -5.46%. The 2025 estimates are for Verrica Pharmaceuticals Inc earnings to increase by 77.70%, but the outlook for the next 5-year period is at 76.18% per year.
VRCA Dividends
Verrica Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-13.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 44.37% of Verrica Pharmaceuticals Inc shares while 31.90% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 57.34%. There are 31.90% institutions holding the Verrica Pharmaceuticals Inc stock share, with PERCEPTIVE ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 15.2663% of the shares, roughly 7.1 million VRCA shares worth $51.75 million.
AVORO CAPITAL ADVISORS LLC holds the second largest percentage of outstanding shares, with 8.6017% or 4.0 million shares worth $29.16 million as of 2024-06-30.
